Drug compound could be next-generation treatment for aggressive form of leukemia - (ScienceDaily via NewsPoints Desk)

  • Researchers writing in EBioMedicine say they have developed a series of compounds that work not only on acute myeloid leukemia (AML) with common FLT3 mutations, but also drug-resistant AML harboring problematic mutations, such as the gatekeeper F691L mutation, reported ScienceDaily.

  • "These compounds have a great potential to be the next-generation AML therapeutics for relapsed patients who no longer respond to first- or second-generation FLT3 inhibitors," said study leader Herman Sintim.

  • The compounds the researchers are studying, alkynyl aminoisoquinoline and alkynyl napthyridine, have been successful in preclinical studies, Sintim said.

  • "In mouse studies, almost no leukemia burden was visible after compound treatment for only a few weeks. Crucially this new class of FLT3 inhibitor also works against drug-resistant secondary mutations, such as the problematic F691L mutation," Sintim added.

  • The scientist noted that the compounds they are developing have shown no signs of toxicity.

  • According to the news source, inhibitors of FLT3, such as Radapt, approved last year by the FDA, have shown good initial response to treating leukemia. Gilteritinib, another FLT3 inhibitor, was approved toward the end of 2018.

To read more NewsPoints articles, click here.